Bio-Techne (FRA:TE1) Short Interest

View and export this data going back to 2000. Start your Free Trial

What is Bio-Techne Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Bio-Techne's Short Interest

For the Biotechnology subindustry, Bio-Techne's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bio-Techne's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bio-Techne's Short Interest distribution charts can be found below:

* The bar in red indicates where Bio-Techne's Short Interest falls into.

Bio-Techne (FRA:TE1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bio-Techne Corp (FRA:TE1) » Definitions » Short Interest

Comparable Companies

Traded in Other Exchanges

TECH:USA T1CH34:Brazil

Address

614 McKinley Place N.E., Minneapolis, MN, USA, 55413

Website

https://www.bio-techne.com

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.

Bio-Techne (FRA:TE1) Headlines

No Headlines